Your browser is no longer supported. Please, upgrade your browser.
Nabriva Therapeutics plc
Index- P/E- EPS (ttm)-2.13 Insider Own1.50% Shs Outstand50.53M Perf Week-7.08%
Market Cap49.71M Forward P/E- EPS next Y-0.67 Insider Trans5.51% Shs Float- Perf Month-27.10%
Income-54.20M PEG- EPS next Q-0.15 Inst Own7.10% Short Float- Perf Quarter-20.97%
Sales22.10M P/S2.25 EPS this Y51.50% Inst Trans-10.31% Short Ratio1.53 Perf Half Y-39.17%
Book/sh1.25 P/B0.68 EPS next Y59.30% ROA-67.30% Target Price2.67 Perf Year-80.47%
Cash/sh0.88 P/C0.96 EPS next 5Y- ROE-98.30% 52W Range0.81 - 4.58 Perf YTD-65.06%
Dividend- P/FCF- EPS past 5Y53.00% ROI-169.20% 52W High-81.54% Beta1.66
Dividend %- Quick Ratio3.70 Sales past 5Y5.90% Gross Margin62.70% 52W Low4.40% ATR0.07
Employees72 Current Ratio4.50 Sales Q/Q584.60% Oper. Margin- RSI (14)28.20 Volatility6.80% 6.96%
OptionableYes Debt/Eq0.13 EPS Q/Q76.40% Profit Margin- Rel Volume1.11 Prev Close0.83
ShortableYes LT Debt/Eq0.08 EarningsNov 09 AMC Payout- Avg Volume767.30K Price0.85
Recom2.70 SMA20-22.36% SMA50-25.03% SMA200-39.89% Volume855,425 Change1.39%
Mar-19-20Downgrade Wedbush Outperform → Neutral
May-02-19Upgrade Gabelli & Co Sell → Hold
May-02-19Reiterated H.C. Wainwright Buy $9 → $7
Sep-07-18Resumed Morgan Stanley Overweight
Mar-21-18Initiated BofA/Merrill Buy $10
Jan-17-18Initiated Morgan Stanley Overweight
Nov-01-17Reiterated H.C. Wainwright Buy $18 → $20
Aug-25-17Initiated SunTrust Buy $20
Feb-01-17Reiterated Wedbush Outperform $13
Oct-27-16Resumed Leerink Partners Outperform $14
Sep-08-16Initiated H.C. Wainwright Buy $16
Jan-27-16Initiated Gabelli & Co Buy $14
Nov-12-15Reiterated RBC Capital Mkts Outperform $21 → $22
Oct-13-15Initiated Wedbush Outperform
Oct-13-15Initiated RBC Capital Mkts Outperform $21
Oct-13-15Initiated Leerink Partners Outperform $19
Oct-12-15Initiated Needham Buy $15
Nov-29-21 09:00AM  
Nov-24-21 10:00AM  
Nov-18-21 06:23AM  
Nov-11-21 07:01AM  
Nov-09-21 04:01PM  
Nov-05-21 07:01AM  
Nov-01-21 07:01AM  
Oct-26-21 07:01AM  
Oct-15-21 04:05PM  
Oct-05-21 08:01AM  
Oct-04-21 04:05PM  
Oct-01-21 04:05PM  
Sep-30-21 08:00AM  
Sep-24-21 07:01AM  
Sep-16-21 09:03AM  
Sep-09-21 10:02AM  
Sep-08-21 07:01AM  
Sep-01-21 07:01AM  
Aug-31-21 04:05PM  
Aug-05-21 04:01PM  
Aug-03-21 04:27PM  
Jul-22-21 07:01AM  
Jul-14-21 10:00AM  
Jul-09-21 04:05PM  
Jun-18-21 03:03PM  
Jun-11-21 05:16AM  
Jun-08-21 11:07AM  
Jun-03-21 07:01AM  
Jun-02-21 06:02PM  
Jun-01-21 07:01AM  
May-26-21 06:53AM  
May-25-21 05:00PM  
May-21-21 07:01AM  
May-06-21 04:01PM  
May-05-21 11:51AM  
May-03-21 04:05PM  
Apr-30-21 10:28AM  
Apr-29-21 04:05PM  
Apr-15-21 12:12PM  
Apr-14-21 09:38AM  
Apr-09-21 09:40AM  
Apr-06-21 09:05AM  
Apr-05-21 06:39AM  
Apr-02-21 04:01PM  
Apr-01-21 08:17AM  
Mar-25-21 07:57AM  
Mar-18-21 08:57AM  
Mar-16-21 08:00AM  
Mar-11-21 04:07PM  
Mar-09-21 07:27AM  
Mar-03-21 04:05PM  
Mar-01-21 08:00AM  
Feb-26-21 08:00AM  
Feb-17-21 10:04AM  
Feb-02-21 08:05AM  
Feb-01-21 04:30PM  
Jan-05-21 04:01PM  
Dec-10-20 11:18PM  
Dec-07-20 07:00AM  
Dec-02-20 08:00AM  
Nov-12-20 07:01AM  
Nov-05-20 04:01PM  
Nov-03-20 06:06AM  
Nov-02-20 04:01PM  
Oct-13-20 07:00AM  
Sep-10-20 08:39AM  
Aug-31-20 07:00AM  
Aug-06-20 04:01PM  
Aug-03-20 07:00AM  
Jul-30-20 04:01PM  
Jul-29-20 10:21AM  
Jul-28-20 10:02AM  
Jul-23-20 07:00AM  
Jul-17-20 11:12AM  
Jul-16-20 04:04PM  
Jul-15-20 04:01PM  
Jun-23-20 09:12PM  
Jun-22-20 03:23PM  
Jun-19-20 08:52PM  
Jun-10-20 08:39AM  
Jun-08-20 07:19AM  
Jun-01-20 04:00PM  
May-29-20 07:31PM  
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schroeder Theodore RChief Executive OfficerSep 14Buy1.1350,00056,500226,875Sep 15 08:00 PM
Webster Stephen WDirectorAug 02Sale1.2077793219,273Aug 04 09:08 PM
BURGESS DANIEL DDirectorAug 02Sale1.201,1251,35021,725Aug 04 09:07 PM
Broom Colin MDDirectorAug 02Sale1.2053163741,862Aug 04 09:06 PM
Rowland Charles A JrDirectorAug 02Sale1.2077793223,773Aug 04 09:05 PM
Bourdow Carrie L.DirectorAug 02Sale1.2077793218,473Aug 04 09:04 PM